Achilles Therapeutics plc (ACHL)
Mar 20, 2025 - ACHL was delisted pending liquidation
1.480
0.00 (0.00%)
Inactive · Last trade price on Mar 21, 2025

Achilles Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018
Selling, General & Admin
15.9717.0121.1221.9711.14.7
Upgrade
Research & Development
55.9658.1550.0642.1222.639.07
Upgrade
Operating Expenses
71.9375.1671.1864.133.7313.78
Upgrade
Operating Income
-71.93-75.16-71.18-64.1-33.73-13.78
Upgrade
Currency Exchange Gain (Loss)
-1-13.82.50.1-0.4
Upgrade
Other Non Operating Income (Expenses)
6.647.083.520.630.430.19
Upgrade
EBT Excluding Unusual Items
-66.29-69.07-63.87-60.96-33.2-13.99
Upgrade
Asset Writedown
-0.1-0.1-7.2-0.1--
Upgrade
Pretax Income
-66.39-69.17-71.07-61.06-33.2-13.99
Upgrade
Income Tax Expense
0.490.490.110.040-
Upgrade
Net Income
-66.88-69.67-71.18-61.1-33.2-13.99
Upgrade
Net Income to Common
-66.88-69.67-71.18-61.1-33.2-13.99
Upgrade
Shares Outstanding (Basic)
4040392911
Upgrade
Shares Outstanding (Diluted)
4040392911
Upgrade
Shares Change (YoY)
1.45%2.13%36.59%2587.54%66.03%18.35%
Upgrade
EPS (Basic)
-1.66-1.74-1.82-2.13-31.14-21.79
Upgrade
EPS (Diluted)
-1.66-1.74-1.82-2.13-31.14-21.79
Upgrade
Free Cash Flow
-64.07-49.55-67.05-66.92-37.1-15.08
Upgrade
Free Cash Flow Per Share
-1.59-1.24-1.71-2.33-34.80-23.49
Upgrade
EBITDA
-67.23-70.44-67.49-60.81-32.96-13.47
Upgrade
D&A For EBITDA
4.74.713.693.290.770.3
Upgrade
EBIT
-71.93-75.16-71.18-64.1-33.73-13.78
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q